In the era of BCR/bcl-2 inhibitors, it has been suggested that historically, poor-risk CLL (e.g., with TP53 mutation) should initially be treated with novel agents and transplanted when this therapy fails or unacceptable toxicities occur. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.